STREAM BIOMEDICAL

Platform Therapy for Neurodegenerative Disease
TBI | CTE | Alzheimer's Disease | Stroke

Turning irreversible into recoverable.

A first-in-class biologic therapy that restores the brain's natural ability to repair itself after injury or disease.

January 2026 | Non-Confidential Deck

William D. Schwieterman, M.D.
CEO, Stream Biomedical Inc.
251-377-4828 | wds@streambiomed.com

streambiomedical.com

For Millions Living With Brain Injury, Recovery Hasn't Been Possible — Until Now

Each year, **more than 90 million people** worldwide experience stroke, traumatic brain injury, or Alzheimer's disease —conditions that cause lasting brain damage and loss of independence.

Despite decades of research, no approved therapy repairs the brain. Current treatments only slow decline or manage symptoms.

Stream Biomedical is leading the development of the first biologic designed to restore it.

Introducing the First Biologic Designed to Repair the Injured Brain

Stream Biomedical is a **clinical-stage** biotechnology company developing **LG3**, **a first-in-class protein** that activates the brain's **natural repair mechanisms** to restore function after injury or disease, including **stroke, traumatic brain injury, and Alzheimer's disease.**

Value Proposition: $10B+ Market Opportunity

Lead Acute Program: TBI

Q4 2027 Clinical Data Readout

Clinical TBI Program will accelerate approval of chronic applications in Alzheimer's Disease and CTE.

Chronic Program:
Alzheimer's Disease (AD)

Chronic Program:
CTE and AD-Related Dementia

How LG3 Restores the Brain's Natural Repair System

Repairs the blood–brain barrier

Protects and stabilizes brain cells

Blocks inflammatory cascades

Reactivates natural neurorepair

By combating shared pathologies, LG3 has potential across multiple conditions.

Preclinical Evidence

Support for this work provided by Angel investors, NINDS SBIR Award R44 NS107152, and NIA SBIR R43 AG063619, and Series A Capital.

Field-Leading Academic Collaborators

University of Texas Health Science Center

TBI and Alzheimer's

University of Kentucky Stroke Core

Stroke

Hubbard Lab
University of Kentucky

TBI and Alzheimer's

McCreedy Lab
Texas A&M University

SCI and Stroke

Bix Lab
Tulane Medical Center

Stroke

Support for this work provided by Angel investors, NINDS SBIR Award R44 NS107152, and NIA SBIR R43 AG063619, and Series A Capital.

LG3 Restores Stroke-Injured Vasculature

A single dose after reperfusion provides profound clinical benefit



Vessel Density: 8.25% (57% loss)



Vessel Density: 18.92% (2% loss)

Healthy Tissue Vessel Density: 19.19%

Brain Tissue Clearing + Light Sheet Microscopy 72hr Post 1-hour transient MCAO Stroke in mice, TAMU/Stream 2025

LG3 Effective in Traumatic Brain Injury

- Highly efficacious with a single dose
- Reduces cell death
- Rapidly improves functional performance
- Improves BBB integrity in impact region



Mouse Studies - UTHSC/Stream Internal Data. (top) Penetrating CCI-TBI young adult male mice.

LG3 Effective in Alzheimer's Model

- Reduces Alzheimer's (AD) plaque burden
- Improves blood-brain barrier integrity
- Improves Alzheimer's-related behavioral and functional deficits



5xFAD Amyloidosis Model, Stream/UTHSC Internal Data.

LG3 Effective in Acute Stroke and tPA-induced Hemorrhage

- **Highly efficacious neuroprotection with single dose**
- **Reduces mortality & brain damage preclinically**
- **Improves tPA (tissue plasminogen activator) safety by reducing hemorrhage risk**



Biose et. al., 2022. Translational Stroke Res; Stream internal data. Preclinical observations and data- (top) young adult male mice, 60' dMCAO; (bottom) aged M&F rats, 90' tMCAO.

LG3 Effective in a Spinal Cord Injury Model

- Improves Limb Function & Weight Support
- Accelerates Recovery Trajectory
- Effective in males and females



TAMU/Stream Internal Data. Basso Motor Score

The Path Forward

Worldwide Protection and New IP:

Exclusive Rights to 2nd Generation Matrikines

Perlecan LG3

Laminin α2-LG5



Stream holds right to entire vascular matrikine family of therapeutic proteins

- **Conserved laminin G-like globular (LG) domains (Matrikine Family)**
- **Composition of matter**
- **Methods of use**
- **Exclusive worldwide license to 3 patent families from Texas A&M University**
- **Recent provisional filings cover entire matrikine family – expiry in 2045**



Issued Patents

Near-Term Value Creating Events

Safety and Efficacy in Humans



Why TBI?

Advantages of Selecting TBI for First Indication

1) Acute Indication with short time to trial readout

2) Clinical Imaging (MRI) correlates directly with LG3's effect on the brain

3) Blood Biomarkers respond rapidly to LG3 treatment

Springboard to CTE and Alzheimer's Disease

Clinical development of second-generation molecule (STR-105)

Raising $15M – Series A extended round via equity financing

$34.2M valuation (flat-round, post-Series A)

Utilization of Funds

- Phase 1 Trial - $1.5M
- Phase 2 Trial - $7.5M
- CMC & Regulatory - $1.5M
- G&A - $2.0M
- 2nd Gen Dev (STR-105) - $2.5M



Milestones

- Q2 2026 - Regulatory Acceptance
- Q4 2026 - Phase 1 Safety Trial Readout
- Q4 2027 - Phase 2 Efficacy Trial Readout

Exit Strategy: Multiple Options

10-40x Potential Valuation following positive Clinical Trial Readout

- **Strategic Acquisition** – following evidence of efficacy (P2 TBI Study)
  - Extending therapeutic window for tPA administration
  - Prevention of hemorrhagic ARIA – dangerous side effect of recently approved anti-amyloid monoclonal therapies
- **Asset Sale / Indication specific Licensing** (i.e. direct payment + royalties)
  - 12 years of biologics exclusivity pending product approval
- **IPO**

Startup (Target)	Acquirer	Share price	Purchase Price (Approx.)
AveXis, Inc.	Novartis	$218/share	**$8.7B**
Receptos, Inc.	Celgene	$232/share	**$7.2B**
Juno Therapeutics, Inc.	Celgene	$87/share	**$9.0B**

Potential Acquirers: Major Biologics Players in Neuro-Injury and Degeneration Space

Roche Biogen Eisai Lilly A MEDICINE COMPANY Johnson&Johnson

Our Team

The Team Turning Irreversible into Recoverable

Stream Leadership

CEO
Bill Schwieterman, MD

CSO
Davis Adkisson, PhD

Dir. Research
Bryan Clossen, PhD

Dir. Manufacturing
Seth Fisher, BA

Scientific Advisory Board

Lennart Mucke, MD

Founding director of the Gladstone Institute of Neurological Disease, UCSF

Ramon Diaz-Arrastia, MD, PhD

Presidential Professor of Neurology at the University of Pennsylvania Perlman School of Medicine in Philadelphia

Andrew Shih, PhD

Professor at the Norcliffe Foundation Center for Integrative Brain Research at Seattle Children's Research Institute.

STREAM BIOMEDICAL

- Turning Irreversible Into Recoverable:
  A first-in-class breakthrough biologic to heal the brain
- Clinic-Ready Therapy
- ~ 2 Year Path to Value Inflection (10-40x)
- Springboard to CTE and Alzheimer's Disease